RecruitingPhase 2NCT07032662

Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

A Phase 2b, Multi-center, Randomized, Double-blind, Placebo-controlled Study of IMVT-1402 Treatment in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Sponsor

Immunovant Sciences GmbH

Enrollment

162 participants

Start Date

Mar 18, 2025

Study Type

INTERVENTIONAL

Conditions

Chronic Inflammatory Demyelinating Polyneuropathy

Summary

This is a Phase 2b study to evaluate the efficacy and safety of Imeroprubart in adults with CIDP.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Imeroprubart and a drug called Placebo for people with chronic inflammatory demyelinating polyneuropathy. The study is currently recruiting participants at 141 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGImeroprubart

Dose 1 subcutaneous (SC) once weekly (QW) for 24 weeks (Period 1) and 52 weeks (Period 2)

DRUGPlacebo

Matching placebo SC QW for 24 weeks (Period 1)

Locations(142)

Site Number - 1612

Tucson, Arizona, United States

Site Number - 1618

Carlsbad, California, United States

Site Number - 1637

Mission Hills, California, United States

Site Number - 1619

Orange, California, United States

Site Number - 1607

Rancho Mirage, California, United States

Site Number -1608

San Francisco, California, United States

Site Number - 1626

Parker, Colorado, United States

Site Number - 1621

New Haven, Connecticut, United States

Site Number - 1630

Washington D.C., District of Columbia, United States

Site Number - 1601

Washington D.C., District of Columbia, United States

Site Number - 1603

Maitland, Florida, United States

Site Number - 1606

Miami, Florida, United States

Site Number - 1617

Ormond Beach, Florida, United States

Site Number - 1620

Port Charlotte, Florida, United States

Site Number - 1633

Rockledge, Florida, United States

Site Number - 1632

Chicago, Illinois, United States

Site Number - 1602

Kansas City, Kansas, United States

Site Number - 1611

Nicholasville, Kentucky, United States

Site Number - 1623

Boston, Massachusetts, United States

Site Number - 1625

Worcester, Massachusetts, United States

Site Number - 1629

Detroit, Michigan, United States

Site Number - 1634

Las Vegas, Nevada, United States

Site Number - 1605

New York, New York, United States

Site Number - 1627

New York, New York, United States

Site Number - 1635

Chapel Hill, North Carolina, United States

Site Number - 1610

Charlotte, North Carolina, United States

Site Number - 1624

Canton, Ohio, United States

Site Number - 1631

Yukon, Oklahoma, United States

Site Number - 1614

Portland, Oregon, United States

Site Number - 1616

Philadelphia, Pennsylvania, United States

Site Number - 1622

Houston, Texas, United States

Site Number - 1628

San Antonio, Texas, United States

Site Number - 1613

Milwaukee, Wisconsin, United States

Site Number - 5005

Rosario, Santa Fe Province, Argentina

Site Number - 5002

Buenos Aires, Argentina

Site Number - 5006

Buenos Aires, Argentina

Site Number - 5001

Córdoba, Argentina

Site Number - 5003

Córdoba, Argentina

Site Number - 5000

Rosario, Argentina

Site Number - 5100

Macquarie Park, Australia

Site Number - 5103

Parkville, Australia

Site Number - 5102

Woolloongabba, Australia

Site Number - 5200

Vienna, Austria

Site Number - 5300

Leuven, Belgium

Site Number - 5400

Banja Luka, Bosnia and Herzegovina

Site Number - 5402

Bihać, Bosnia and Herzegovina

Site Number - 5401

Mostar, Bosnia and Herzegovina

Site Number - 5403

Sarajevo, Bosnia and Herzegovina

Site Number - 5507

Belo Horizonte, Brazil

Site Number - 5506

Brasília, Brazil

Site Number - 5503

Campinas, Brazil

Site Number - 5500

Curitiba, Brazil

Site Number - 5502

Joinville, Brazil

Site Number - 5501

Porto Alegre, Brazil

Site Number - 5504

Porto Alegre, Brazil

Site Number - 5505

Vila Clementino, Brazil

Site Number - 5601

Pleven, Bulgaria

Site Number - 5600

Sofia, Bulgaria

Site Number - 5602

Sofia, Bulgaria

Site Number - 5603

Sofia, Bulgaria

Site Number - 5604

Sofia, Bulgaria

Site Number - 5800

Bogotá, Colombia

Site Number - 3600

Copenhagen, Denmark

Site Number - 3601

Odense, Denmark

Site Number - 7251

Tallinn, Estonia

Site Number - 3800

Turku, Finland

Site Number - 6505

Berlin, Germany

Site Number - 6501

Bochum, Germany

Site Number - 6504

Essen, Germany

Site Number - 6500

Tübingen, Germany

Site Number - 6503

Ulm, Germany

Site Number - 6502

Würzburg, Germany

Site Number - 3901

Alexandroupoli, Greece

Site Number - 3902

Athens, Greece

Site Number - 3905

Chaïdári, Greece

Site Number - 3906

Heraklion, Greece

Site Number - 3903

Ioannina, Greece

Site Number - 3904

Larissa, Greece

Site Number - 3900

Pátrai, Greece

Site Number - 7551

Budapest, Hungary

Site Number - 7550

Kistarcsa, Hungary

Site Number - 7552

Pécs, Hungary

Site Number - 4100

Waterford, Ireland

Site Number - 6004

Bergamo, Italy

Site Number - 6007

Bologna, Italy

Site Number - 6000

Brescia, Italy

Site Number - 6009

Milan, Italy

Site Number - 6001

Milan, Italy

Site Number -6005

Milan, Italy

Site Number - 6011

Pavia, Italy

Site Number - 6010

Pisa, Italy

Site Number - 6002

Roma, Italy

Site Number - 6006

Roma, Italy

Site Number - 6003

Siena, Italy

Site Number - 2603

Colonia del Valle, Mexico

Site Number - 2600

Culiacán, Mexico

Site Number - 2602

Tlalpan, Mexico

Site Number - 2601

Veracruz, Mexico

Site Number - 2200

Utrecht, Netherlands

Site Number - 2300

Oslo, Norway

Site Number - 2401

Callao, Peru

Site Number - 2400

Lima, Peru

Site Number - 2403

Miraflores, Peru

Site Number - 3009

Lublin, Lublin Voivodeship, Poland

Site Number - 3007

Bydgoszcz, Poland

Site Number - 3008

Gdansk, Poland

Site Number - 3004

Katowice, Poland

Site Number - 3000

Krakow, Poland

Site Number - 3003

Krakow, Poland

Site Number - 3001

Lublin, Poland

Site Number - 3005

Lublin, Poland

Site Number - 3002

Poznan, Poland

Site Number - 3006

Warsaw, Poland

Site Number -2902

Almada, Portugal

Site Number - 2901

Matosinhos Municipality, Portugal

Site Number - 2903

Vila Nova de Gaia, Portugal

Site Number - 7503

Bucharest, Romania

Site Number - 7500

Constanța, Romania

Site Number - 9000

Belgrade, Serbia

Site Number - 9003

Belgrade, Serbia

Site Number -9002

Kragujevac, Serbia

Site Number - 9001

Niš, Serbia

Site Number - 2800

Martin, Slovakia

Site Number - 2802

Prešov, Slovakia

Site Number - 2801

Rimavská Sobota, Slovakia

Site Number - 7351

Ljubljana, Slovenia

Site Number - 7100

Barcelona, Spain

Site Number - 7101

Barcelona, Spain

Site Number - 7104

Bilbao, Spain

Site Number - 7103

Córdoba, Spain

Site Number - 7102

Santiago de Compostela, Spain

Site Number - 7105

Valencia, Spain

Site Number - 4250

Bakırköy, Turkey (Türkiye)

Site Number - 4253

Başakşehir, Turkey (Türkiye)

Site Number - 4255

Bursa, Turkey (Türkiye)

Site Number - 4251

Istanbul, Turkey (Türkiye)

Site Number - 4254

Izmir, Turkey (Türkiye)

Site Number - 4252

Samsun, Turkey (Türkiye)

Site Number - 7001

Bristol, United Kingdom

Site Number - 7002

Glasgow, United Kingdom

Site Number - 7000

Salford, United Kingdom

Site Number - 7003

Southampton, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07032662

Related Trials

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT067523563 locations

A Study to Evaluate the Efficacy and Safety of DNTH103 in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

NCT06858579180 locations

A Study to Test the Efficacy and Safety of Riliprubart Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in People With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

NCT06290141129 locations

A Study to Assess Efficacy and Safety of Empasiprubart Versus IVIg in Adults With CIDP

NCT0692000482 locations

A Study to Assess the Efficacy and Safety of Empasiprubart in Adults With CIDP

NCT0709163071 locations